The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Feoktistova P.S.

BU KhMAO-IuGRY "Nizhnevartovskiĭ onkologicheskiĭ dispanser"

Zaginaĭko A.V.

BU KhMAO-IuGRY "Nizhnevartovskiĭ onkologicheskiĭ dispanser"

Simanovich E.É.

BU KhMAO-IuGRY "Okruzhnaia klinicheskaia bol'nitsa", Okruzhnoĭ onkologicheskiĭ tsentr

Zharkova O.V.

GBUZ Kemerovskoĭ oblasti "Oblastnoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Mironova E.B.

FGUZ "Klinicheskaia bol'nitsa #81" FMBA Rossii, Seversk

Karaseva V.V.

Kafedra onkologii FUV GBOU VPO "Rossiĭskiĭ natsional'nyĭ meditsinskiĭ universitet im. N.I. Pirogova" Minzdrava Rossii, Moskva

Khaĭlenko V.A.

Kafedra onkologii FUV GBOU VPO "Rossiĭskiĭ natsional'nyĭ meditsinskiĭ universitet im. N.I. Pirogova" Minzdrava Rossii, Moskva

Targeted therapy for metastatic colorectal cancer

Authors:

Feoktistova P.S., Zaginaĭko A.V., Simanovich E.É., Zharkova O.V., Mironova E.B., Karaseva V.V., Khaĭlenko V.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(3): 31‑35

Views: 1120

Downloaded: 15

Download PDF (RU)
Contact the author
Table of contents

TARGETED THERAPY FOR METASTATIC COLORECTAL CANCER
TARGETED THERAPY FOR METASTATIC COLORECTAL CANCER

To cite this article:

Feoktistova PS, Zaginaĭko AV, Simanovich EÉ, Zharkova OV, Mironova EB, Karaseva VV, Khaĭlenko VA. Targeted therapy for metastatic colorectal cancer. P.A. Herzen Journal of Oncology. 2013;2(3):31‑35. (In Russ.)

Подписка 2025-2 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Close metadata
Recommended articles:
Colo­rectal cancer and gut microbiota. P.A. Herzen Journal of Onco­logy. 2024;(2):60-66
Unco­ntrolled inhi­bition of checkpoints. P.A. Herzen Journal of Onco­logy. 2024;(2):67-73
Modern treatment methods for patients with liver meta­stases from uveal mela­noma. P.A. Herzen Journal of Onco­logy. 2024;(2):74-84
Gona­dotropin-releasing hormone agonists as a chance for motherhood in the future. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):30-36
Drug therapy for loca­lly adva­nced and meta­static non-small cell lung cancer with MET muta­tion: indi­rect comparison. Medi­cal Technologies. Asse­ssment and Choice. 2024;(3):82-92
The Russian consensus on the treatment of intrahepatic cholangiocarcinoma. Piro­gov Russian Journal of Surgery. 2024;(10):7-20
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143
New pathogenic treatments for myasthenia gravis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):31-38

Recent statistical data suggest that there is a rise in morbidity and mortality rates of colorectal cancer, which in conjunction with the prevalence of its metastatic forms and common dissemination presents a serious medical problem. The paper gives the data of multicenter clinical trials of the most effective targeted drugs, such as bevacizumab and cetuximab, in the treatment of colorectal cancer. It considers possibilities for current antitumor therapy for metastatic colorectal cancer, by using three patient groups as an example.

Keywords:

metastatic colorectal cancer
chemotherapy
targeted therapy

Authors:

Feoktistova P.S.

BU KhMAO-IuGRY "Nizhnevartovskiĭ onkologicheskiĭ dispanser"

Zaginaĭko A.V.

BU KhMAO-IuGRY "Nizhnevartovskiĭ onkologicheskiĭ dispanser"

Simanovich E.É.

BU KhMAO-IuGRY "Okruzhnaia klinicheskaia bol'nitsa", Okruzhnoĭ onkologicheskiĭ tsentr

Zharkova O.V.

GBUZ Kemerovskoĭ oblasti "Oblastnoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Mironova E.B.

FGUZ "Klinicheskaia bol'nitsa #81" FMBA Rossii, Seversk

Karaseva V.V.

Kafedra onkologii FUV GBOU VPO "Rossiĭskiĭ natsional'nyĭ meditsinskiĭ universitet im. N.I. Pirogova" Minzdrava Rossii, Moskva

Khaĭlenko V.A.

Kafedra onkologii FUV GBOU VPO "Rossiĭskiĭ natsional'nyĭ meditsinskiĭ universitet im. N.I. Pirogova" Minzdrava Rossii, Moskva

List of references:

  1. Garin A.M., Bazin I.S. Desyat' naibolee rasprostranennykh zlokachestvennykh opukholei. M.: MAKS Press; 2010. 143 s.
  2. Garin A.M. Rak tolstoi kishki. M.; 1998. 58 s.
  3. Myers M.H., Ries L.A. Cancer patients survival rates: SEER program results for 10 years of follow-up. CA Sancer J. Clin. 1989; 39 (1): 21-32.
  4. Wingo P.A., Tong T., Bolden S. Cancer statistics, 1995. CA Cancer J. Clin. 1995; 45 (1): 8-30.
  5. Garin A.M., Bazin I.S., red. Spravochnoe rukovodstvo po lekarstvennoi terapii solidnykh opukholei. M.: MAKS Press; 2010: 210-1.
  6. Piessevaux H. et al. JSMO. 2012: abstr. No ES 9-3.
  7. Renouf D.J., Lim H.J., Speers C., Villa D., Gill S., Blanke C.D. et al. Survival for metastatic colorectal cancer in bevacizumab era: a population-based analysis. Clin. Colorectial Cancer. 2011; 10 (2): 97-101.
  8. Tryakin A.A. Targetnaya terapiya kolorektal'nogo raka, raka zheludka i podzheludochnoi zhelezy. Prakticheskaya onkologiya. 2010; 11 (3): 143-50.
  9. Perevodchikova N.I., red. Rukovodstvo po khimioterapii opukholevykh zabolevanii. M.: Prakticheskaya meditsina; 2013. 164 s.
  10. Meierkhardt Dzh., Sanderz M., red. Rak tolstoi kishki. M.: Rid Elsilver; 2009. 84 s.
  11. Grothey A., Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat. Rev. Clin. Oncol. 2009; 6: 507-18.
  12. Imyanitov E.N. Obshchie predstavleniya o targetnoi terapii. Prakticheskaya onkologiya. 2010; 11 (3).
  13. Grothey A., Sugrue M.M., Purdie D.M., Dong W., Sargent D., Hedrick E., Kozloff M. Bevacizumab beyong first progression bis associated with prolonged overall survival in metastatic colorectal cancer: Result from a large observational cohort study (BRite). J. Clin. Oncol. 2008; 26 (33): 5326-34.
  14. Van Cutsem E., Lang I., Folprecht G., Nowacki S., Shchepotin I., Maurel J. et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. In: ASCO Gastrointestinal cancers symposium. Orlando; 2010: abstr. 281.
  15. Artamonova E.V., Maznyuk L.V. Kozhnaya toksichnost' blokatorov EGFR (po dannym klinicheskikh issledovanii tsetuksimaba). Effektivnaya farmakoterapiya. Onkologiya, gematologiya i radiologiya. 2012; 1: 26-31.
  16. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009; 6 (8): 465-77.
  17. Randall L.M., Monk B.J. Bevacizumab toxicities and their management in ovarian cancer. Gynecol. Oncol. 2010; 117 (3): 497-504.
  18. Tol J., Punt C.J. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin. Ther. 2010; 32 (3): 437-54.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.